Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

President Trump has urged major pharmaceutical companies to reduce US prescription drug prices, aligning them with the lowest ...

President Donald Trump escalated his campaign to pressure pharmaceutical companies to lower drug prices, sending letters to 17 of the world’s largest drugmakers demanding they charge the U.S. what oth ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

None of the price-target hikes were particularly dramatic, but since they came from analysts already bullish on AbbVie, they ...

Analysts have set 12-month price targets for AbbVie, revealing an average target of $230.75, a high estimate of $255.00, and a low estimate of $205.00. Marking an increase of 2.21%, the current ...

They comprise 2.4% of the broader U.S. Market Index, yet are up 10.7% year-to-date. Compare that to technology stocks, which ...

(Reuters) -Drugmaker AbbVie is in talks to acquire privately-held mental health therapeutics company Gilgamesh ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.